Shilpa Medicare gets USFDA Import Alert for formulations unit
API and formulations maker, Shilpa Medicare Limited, has received an import alert 66-40 from the US Food and Drug Administration (USFDA) to the compan18-02-2021
18-02-2021
SHILPA MEDICARE LTD. - 530549 - Announcement U/R 30 Of SEBI (LODR) Regulations 2015
Information about receipt of Import Alert 66-4018-02-2021
SHILPA MEDICARE LTD. - 530549 - Announcement U/R 30 Of SEBI (LODR) Regulations 2015
Import Alert Issued by USFDA to Shilpa Medicare's Formulation's Manufacturing Unit at Pharma SEZ, TSIIC, Polepally, Jadcherla, Mahbubnagar, Telangana, India18-02-2021
Buy Shilpa Medicare; target of Rs 520: Sharekhan
Sharekhan is bullish on Shilpa Medicare has recommended buy rating on the stock with a target price of Rs 520 in its research report dated February 12, 2021.16-02-2021
Shilpa Medicare launches Sunitinib capsules in India; stock down 5%
The Sunitinib capsule has proven to be bioequivalent to sutent capsules of Pfizer.15-02-2021
SHILPA MEDICARE LTD. - 530549 - Intimation Under Regulation 30 Of SEBI (LODR) 2015
Shilpa Medicare Limited Launches Sunitinib Capsules under the brand name SUNISHIL in India15-02-2021
SHILPA MEDICARE LTD. - 530549 - EVENTS AND INFORMATION DISCLOSURE
This is to intimate that Shilpa Medicare Limited Promoted 'Koanna International FZ-LLC' in Dubai making it as a Wholly Owned Subsidiary for the Business Operations of the Company.13-02-2021
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find herewith enclosed copy of 03rd Quarter of Financial Year 2020-21 Results presentation made to analysts and Investors13-02-2021
SHILPA MEDICARE LTD. - 530549 - Results For Quarter Ended 31St December, 2021
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 13th February, 2021 at 12:00 Noon the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2020 pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015.13-02-2021
SHILPA MEDICARE LTD. - 530549 - Outcome Of Board Meeting Held On 13Th February, 2021.
With reference to the captioned subject, Please be noted that pursuant to the Resolution passed at the meeting of the board of directors held on 13th February, 2021 at 12:00 Noon the following items have taken on record. 1. The unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2020 pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015. The meeting commenced at 12:00 Noon and concluded at 01:35 pm13-02-2021